BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Colapietro F, Pugliese N, Voza A, Aghemo A, De Nicola S. Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis. World J Gastroenterol 2024; 30(9): 1253-1256 [PMID: 38577192 DOI: 10.3748/wjg.v30.i9.1253]
URL: https://www.wjgnet.com/1948-5182/full/v30/i9/1253.htm
Number Citing Articles
1
Wei-Nung Liu, Ming-Shen Dai, Felicia Lin, Gen-Min Lin. Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitorsWorld Journal of Gastroenterology 2024; 30(21): 2748-2750 doi: 10.3748/wjg.v30.i21.2748
2
AcalabrutinibReactions Weekly 2024; 2007(1): 17 doi: 10.1007/s40278-024-58577-y
3
Bansi P Savaliya, Ramin Shekouhi, Fatima Mubarak, Harsheen K Manaise, Paola Berrios Jimenez, Gabrielle Kowkabany, Reed A Popp, Kyle Popp, Emmanuel Gabriel. Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitorsWorld Journal of Gastroenterology 2024; 30(24): 3052-3058 doi: 10.3748/wjg.v30.i24.3052
4
Michele Barone. Risk of hepatic decompensation from hepatitis B virus reactivation in hematological malignancy treatmentsWorld Journal of Gastroenterology 2024; 30(25): 3147-3151 doi: 10.3748/wjg.v30.i25.3147
5
Sergey Morozov, Sergey Batskikh. Reactivation of hepatitis B virus infection – an important aspect of multifaceted problemWorld Journal of Gastroenterology 2024; 30(26): 3193-3197 doi: 10.3748/wjg.v30.i26.3193